178 related articles for article (PubMed ID: 22227465)
21. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
Van Welzen B; Mudrikova T; Arends J; Hoepelman A
HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
[TBL] [Abstract][Full Text] [Related]
22. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
[TBL] [Abstract][Full Text] [Related]
23. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
24. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
[TBL] [Abstract][Full Text] [Related]
25. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
27. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
28. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
[TBL] [Abstract][Full Text] [Related]
29. Nelfinavir and nevirapine side effects during pregnancy.
Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
[TBL] [Abstract][Full Text] [Related]
30. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md
Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464
[TBL] [Abstract][Full Text] [Related]
31. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
[TBL] [Abstract][Full Text] [Related]
32. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
[TBL] [Abstract][Full Text] [Related]
33. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
[TBL] [Abstract][Full Text] [Related]
34. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
Torti C; Lapadula G; Puoti M; Casari S; Uccelli MC; Cristini G; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Caputo SL; Bonora S; Carosi G
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):180-5. PubMed ID: 16394850
[TBL] [Abstract][Full Text] [Related]
35. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age.
Snijdewind IJM; Smit C; Godfried MH; Bakker R; Nellen JFJB; Jaddoe VWV; van Leeuwen E; Reiss P; Steegers EAP; van der Ende ME
PLoS One; 2018; 13(1):e0191389. PubMed ID: 29351561
[TBL] [Abstract][Full Text] [Related]
36. Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Edwards SG; Larbalestier N; Hay P; de Ruiter A; Welch J; Taylor GP; Easterbrook P
HIV Med; 2001 Apr; 2(2):89-91. PubMed ID: 11737384
[TBL] [Abstract][Full Text] [Related]
37. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
[TBL] [Abstract][Full Text] [Related]
38. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
[TBL] [Abstract][Full Text] [Related]
39. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
[TBL] [Abstract][Full Text] [Related]
40. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]